The company's predecessor, Jiangxi Boya Biopharmaceutical Co., Ltd., was founded in 1993. It is a comprehensive medical industry group focusing on blood products, integrating biochemicals, chemicals, APIs, etc., and is headquartered in Fuzhou City, Jiangxi Province, where Renjie Diling is located. The company successfully landed on the China Shenzhen Stock Exchange GEM in March 2012 (stock code: 300294). The company is mainly engaged in R&D, production and sales of blood products, including three types of products: albumin, immunoglobulins and coagulation factors. The company is one of the leading manufacturers of blood products in China. Its products cover 9 varieties of 23 specifications, including human blood albumin, intravenous human immunoglobulin (pH4), and coagulation factors. Corporate honors: It has successively won honorary awards such as Forbes China's Top 100 Potential Listed Companies in 2013, 2014 and 2016, China's Top 50 Listed Companies in 2014, China's Top 100 Listed Companies Most Respected by Investors in 2015, China's Top 150 Listed Companies by Jinniu Value Investors in 2016, and Top 10 Pharmaceutical Companies with the Most Investment Value in 2017.
No Data